Immunicum to Participate in Upcoming Conferences

Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following upcoming conferences:

 

Redeye Growth Day 2022

June 2, 2022

Immunicum CEO Erik Manting will participate in an on-site Q&A session on June 2, at 08:55 am CET. Further details including the on-demand corporate presentation are available via:
https://redeye.ifairs.com/#/booth?id=687

 

BioStock Life Science Spring Summit

June 8-9, 2022

Immunicum CEO Erik Manting will present on June 9, at 10:20 am CET.

https://www.biostock.se/en/2022/04/biostock-life-science-spring-summit-june-8-9/

 

European Hematology Association (EHA) 2022 Congress

June 9-17, 2022

https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/

 

BIO International Convention

June 13-16, 2022

https://www.bio.org/events/bio-international-convention

 

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@immunicum.com

 

INVESTOR RELATIONS

Julie Seidel

Stern Investor Relations

Telefon: +1 212-362-1200

E-mail: julie.seidel@sternir.com

 

MEDIA RELATIONS

Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu

 

ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for blood-borne and solid tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

 

Attachment

Keep reading

Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment